(Q35159127)

6 August 2017

1 reference

title

A novel approach to thrombin inhibition (English)

1 reference

6 August 2017

1

Jeffrey I Weitz

1 reference

6 August 2017

publication date

1 July 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

109 Suppl 1

1 reference

6 August 2017

page(s)

S17-22

1 reference

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

The emerging role of low-molecular-weight heparin in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Reactivation of unstable angina after the discontinuation of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

The development of hirudin as an antithrombotic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

New thrombin inhibitors in cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Clinical outcomes of bivalirudin for ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2803%2900251-2

7 January 2021

10.1016/S0049-3848(03)00251-2

Identifiers

DOI

1 reference

6 August 2017

1 reference